search
Back to results

Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit

Primary Purpose

Cirrhosis With Septic Shock

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Terlipressin
Noradrenaline
Sponsored by
Institute of Liver and Biliary Sciences, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cirrhosis With Septic Shock

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient of cirrhosis or ACLF (Acute on Chronic Liver Failure) with septic shock (defined later).
  • Age 18-70yrs
  • An informed consent from the patient or relative

Exclusion Criteria:

  • Pronounced cardiac dysfunction( valvular heart disease, coronary artery disease),
  • Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g. Reynaud's syndrome or related diseases).
  • Pregnancy
  • Previous history of transplantation on immunosuppressant.
  • Acute gastrointestinal bleed.(defined later)

Sites / Locations

  • Institute of liver and Biliary Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Noradrenaline

Terlipressin

Arm Description

Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.

Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.

Outcomes

Primary Outcome Measures

The Hemodynamic improvement as defined as mean arterial pressure > 65 mmHg.

Secondary Outcome Measures

Mortality
Number of organ system involved as defined by SOFA (Sequential Organ Failure Assessment)
Days free of vasopressors
Days free of ventilatory support
Days free of steroid
Length of stay
Incidence of serious adverse events.

Full Information

First Posted
April 2, 2013
Last Updated
November 21, 2016
Sponsor
Institute of Liver and Biliary Sciences, India
search

1. Study Identification

Unique Protocol Identification Number
NCT01836224
Brief Title
Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit
Official Title
A Prospective Open Label Randomized Non Inferiority Trial to Compare the Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The Patient evaluated in Emergency room since admission and detailed history and clinical examination done .The in hospital cases where sepsis is the culprit and shifted to Intensive Care Unit (ICU) in view of septic shock were included since onset of shock. Initial fluid resuscitation done and if the patient were no fluid responsive they were randomized into arms noradrenaline or terlipressin and the dose escalated to achieve the primary objectives. At the same time the strict vitals monitoring and standard medical therapy for sepsis including antibiotics and other supportive therapy continued. The patients were followed up till discharge, death or up to 28days after enrollment into the protocol (whichever the longest). The detail methodology has been explained in column 14 later.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis With Septic Shock

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
84 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Noradrenaline
Arm Type
Active Comparator
Arm Description
Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
Arm Title
Terlipressin
Arm Type
Experimental
Arm Description
Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
Intervention Type
Drug
Intervention Name(s)
Terlipressin
Intervention Description
Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
Intervention Type
Drug
Intervention Name(s)
Noradrenaline
Intervention Description
Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
Primary Outcome Measure Information:
Title
The Hemodynamic improvement as defined as mean arterial pressure > 65 mmHg.
Time Frame
48 hrs
Secondary Outcome Measure Information:
Title
Mortality
Time Frame
Day 3, Day 7 and Day 28
Title
Number of organ system involved as defined by SOFA (Sequential Organ Failure Assessment)
Time Frame
Within 28 days
Title
Days free of vasopressors
Time Frame
Within 28 days
Title
Days free of ventilatory support
Time Frame
Within 28 days
Title
Days free of steroid
Time Frame
Within 28 dyas
Title
Length of stay
Time Frame
Within 28 days
Title
Incidence of serious adverse events.
Time Frame
Within 28 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient of cirrhosis or ACLF (Acute on Chronic Liver Failure) with septic shock (defined later). Age 18-70yrs An informed consent from the patient or relative Exclusion Criteria: Pronounced cardiac dysfunction( valvular heart disease, coronary artery disease), Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g. Reynaud's syndrome or related diseases). Pregnancy Previous history of transplantation on immunosuppressant. Acute gastrointestinal bleed.(defined later)
Facility Information:
Facility Name
Institute of liver and Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India

12. IPD Sharing Statement

Citations:
PubMed Identifier
27633962
Citation
Choudhury A, Kedarisetty CK, Vashishtha C, Saini D, Kumar S, Maiwall R, Sharma MK, Bhadoria AS, Kumar G, Joshi YK, Sarin SK. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017 Apr;37(4):552-561. doi: 10.1111/liv.13252. Epub 2016 Oct 20.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit

We'll reach out to this number within 24 hrs